26 September 2016 - When the gold standard in medical abortion drugs finally becomes available in Canada later this year, the $300 cost of the pills will not be covered by most provincial drug plans, The Globe and Mail has learned.

The company that makes Mifegymiso has bowed out of an essential step on the path to public reimbursements for new drugs over the $72,000 price tag for a standard review of the medication’s cost effectiveness.

Provincial governments everywhere but Quebec say the company’s decision is preventing them from adding the two-drug abortion regimen to their list of publicly funded drugs, meaning women will have to reach into their own wallets or rely on private insurance to pay for Mifegymiso.

Read The Globe & Mail article